LY2784544 (JAK2 inhibitor)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-06-23 — A Study of LY2784544 in Participants With Myeloproliferative Neoplasms: Early-phase trial (trial-early) evaluating response rate of LY2784544 (selective JAK2 inhibitor) in PV, ET, and MF, including ruxolitinib-intolerant and ruxolitinib-refractory patients — positions LY2784544 as a candidate salvage JAK2 inhibitor in the post-ruxolitinib setting. (novelty: 3)
Open questions
Related
Contributing findings
A Study of LY2784544 in Participants With Myeloproliferative Neoplasms
23-jun-2026
novelty 3
per-area 3
introduces